Portfolio

LSP 7

Investments range between EUR 30 million and EUR 60 million

LSP 7 seeks to invest in early-to-late-stage life sciences companies, developing novel and ground-breaking new medicines and technologies that provide solutions to unmet medical needs. LSP 7’s geographical focus is primarily Europe and occasionally the US.

René R. Kuijten Partner and Head of EQT Life Sciences
Send email

LSP Advisory B.V.
Johannes Vermeerplein 9
1071 DV Amsterdam, the Netherlands

Company Registration Number: 34296447

LSP Advisory B.V. is an alternative investment fund manager authorized and regulated in accordance with laws of the Netherlands.

Fast facts

  • Status
    Active
  • Launch
    2021
  • Size
    EUR 1 bn
  • SFDR classification
    Art. 8

Investment advisory committee

  • Chairperson
    Prof. dr A. Pijpers
  • Ariceum Therapeutics
  • Egle Therapeutics
  • Evommune
  • HotSpot Therapeutics